Diabetic Nephropathy clinical trials
25 active trials name this condition. Describe your situation to see which ones you may be eligible for.
By location
- Trial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes
- Formoterol in Diabetes
- NAD Augmentation in Diabetes Kidney Disease
- A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4248 in Healthy Participants and Participants With Chronic Kidney Disease and Type 2 Diabetes and to Assess Home Measurements of Creatinine in a Non Interventional Cohort
- Uric Acid Lowering Trial in Youth Onset T2D
- Study to Assess the Effects of Angiopoietin-like Protein 3 (ANGPTL3) Inhibition in Adult Participants With Diabetic Kidney Disease
- Study of WAL0921 in Patients With Glomerular Kidney Diseases
- Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease
- Mechanism of SGLT2 Inhibition in the Kidney
- A Long-Term Follow-Up Study of Participants Exposed to REACT
- Real World Evidence Clinical Utility Study of KidneyIntelX
- Transformative Research in Diabetic Nephropathy 2.0
- Safety and Tolerability of Vertebral Bone Marrow-derived Mesenchymal Stem Cells (BM-MSC) in Real World Scenarios of Patients With Chronic Kidney Disease (CKD)
- Mixed Methods Study of Health-Related Social Needs in African American Adults With Chronic Kidney Disease and Type 2 Diabetes Mellitus
- Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)
- Kidney Precision Medicine Project
- Transformative Research in Diabetic Nephropathy
- Repository of Novel Analytes Leading to Autoimmune, Inflammatory and Diabetic Nephropathies (RENAL AID)
- Role of Finerenone in African American Veterans With Diabetic Kidney Disease
- Precision T1D Platform - New Therapies for Cardio-Renal Complications
- Revealing Engagement Dynamics Among Diabetic Kidney Disease Patients
- Long-Term Follow-up Study of Participants Exposed to Renal Autologous Cell Therapy Frozen Product
- Plant-Focused Nutrition in Patients With Diabetes and Chronic Kidney Disease
- Renal Mechanism of SGLT2 Inhibition
- Pathogenesis of Kidney Disease in Type 1 Diabetes: a Modern Kidney Biopsy Cohort (The PANDA Study)
Guides for people searching for a trial
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that list “Diabetic Nephropathy” as a condition. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.